Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Citi
Accenture
UBS
Cerilliant
Deloitte
Moodys
Teva
Cantor Fitzgerald
US Army

Generated: October 20, 2017

DrugPatentWatch Database Preview

Wyeth Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for WYETH PHARMS INC, and what generic alternatives to WYETH PHARMS INC drugs are available?

WYETH PHARMS INC has thirty-one approved drugs.

There are eighteen US patents protecting WYETH PHARMS INC drugs on WYETH PHARMS INC drugs in the past three years.

There are three hundred and ten patent family members on WYETH PHARMS INC drugs in sixty-four countries and twenty-four supplementary protection certificates in ten countries.

Summary for Applicant: Wyeth Pharms Inc

International Patents:310
US Patents:18
Tradenames:29
Ingredients:19
NDAs:31
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc
PROTONIX
pantoprazole sodium
FOR SUSPENSION, DELAYED RELEASE;ORAL022020-001Nov 14, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-001Oct 20, 1997ABRXYesNo► Subscribe► SubscribeY► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-004Oct 20, 1997ABRXYesYes► Subscribe► SubscribeY► Subscribe
Wyeth Pharms Inc
EFFEXOR
venlafaxine hydrochloride
TABLET;ORAL020151-001Dec 28, 1993DISCNYesNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms Inc
PRISTIQ
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL021992-002Feb 29, 2008ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-004Oct 20, 1997ABRXYesYes► Subscribe► SubscribeY► Subscribe
Wyeth Pharms Inc
PROTONIX IV
pantoprazole sodium
INJECTABLE;IV (INFUSION)020988-001Mar 22, 2001APRXYesYes► Subscribe► SubscribeY► Subscribe
Wyeth Pharms Inc
ZOSYN IN PLASTIC CONTAINER
piperacillin sodium; tazobactam sodium
INJECTABLE;INJECTION050750-003Feb 24, 1998RXYesYes► Subscribe► SubscribeY ► Subscribe
Wyeth Pharms Inc
EFFEXOR
venlafaxine hydrochloride
TABLET;ORAL020151-005Dec 28, 1993DISCNYesNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms Inc
ZOSYN
piperacillin sodium; tazobactam sodium
INJECTABLE;INJECTION050684-001Oct 22, 1993APRXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Wyeth Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms Inc
PREMARIN
estrogens, conjugated
TABLET;ORAL004782-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Wyeth Pharms Inc
PREMPRO
estrogens, conjugated; medroxyprogesterone acetate
TABLET;ORAL-28020527-001Nov 17, 1995► Subscribe► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-001Oct 20, 1997► Subscribe► Subscribe
Wyeth Pharms Inc
MYLOTARG
gemtuzumab ozogamicin
INJECTABLE;INJECTION021174-001May 17, 2000► Subscribe► Subscribe
Wyeth Pharms Inc
PREMPRO (PREMARIN;CYCRIN)
estrogens, conjugated; medroxyprogesterone acetate
TABLET;ORAL-28020303-001Dec 30, 1994► Subscribe► Subscribe
Wyeth Pharms Inc
TRIPHASIL-28
ethinyl estradiol; levonorgestrel
TABLET;ORAL-28019190-001Nov 1, 1984► Subscribe► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-004Oct 20, 1997► Subscribe► Subscribe
Wyeth Pharms Inc
PREMPRO
estrogens, conjugated; medroxyprogesterone acetate
TABLET;ORAL-28020527-003Jan 9, 1998► Subscribe► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-002Oct 20, 1997► Subscribe► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-003Oct 20, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for WYETH PHARMS INC drugs

Drugname Dosage Strength Tradename Submissiondate
desvenlafaxine succinate
Extended-release Tablets 25 mg
PRISTIQ
5/8/2015
desvenlafaxine succinate
Extended-release Tablets50 mg and 100 mg
PRISTIQ
2/29/2012
piperacillin sodium and tazobactam sodium
For Injection12 g/1.5 g per vial (pharmacy bulk)
ZOSYN
12/6/2011
levonorgestrel and ethinyl estradiol
Tablets0.09 mg/0.02 mg
LYBREL
10/5/2007
venlafaxine hydrochloride
Extended-release Tablets37.5 mg, 75 mg and 150 mg
EFFEXOR XR
5/3/2007
venlafaxine hydrochloride
Tablets25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg
EFFEXOR
11/3/2005
pantoprazole sodium
Delayed-release Tablets20 mg and 40 mg
PROTONIX
2/2/2004

Non-Orange Book Patents for Wyeth Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,026,508Succinate salt of O-desmethyl-venlafaxine► Subscribe
7,498,312Compositions containing piperacillin and tazobactam useful for injection► Subscribe
7,291,347Succinate salt of O-desmethyl-venlafaxine► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Wyeth Pharms Inc Drugs

Country Document Number Estimated Expiration
European Patent Office1165487► Subscribe
South Africa200303593► Subscribe
Hungary224617► Subscribe
Denmark0589981► Subscribe
European Patent Office0797991► Subscribe
Australia2004229407► Subscribe
Georgia, Republic ofP20043198► Subscribe
Cyprus1106952► Subscribe
Hong Kong1057885► Subscribe
Georgia, Republic ofP20053461► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Wyeth Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0030France► SubscribePRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
C/GB99/008United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
00095Netherlands► SubscribePRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
2009 00017Denmark► SubscribePRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
00C/027Belgium► SubscribePRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
0443983/03Switzerland► SubscribePRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
1214076/01Switzerland► SubscribePRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
323Luxembourg► SubscribePRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624
0814Netherlands► SubscribePRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
156Luxembourg► SubscribePRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Covington
Argus Health
McKesson
Chinese Patent Office
Mallinckrodt
Chubb
Baxter
Julphar
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot